Informing Biomarkers for Multi-Specific Immune Cell Engagers Using Preclinical Models
- T and NK cells mediate anti-tumor activity by multiple mechanisms in the tumor microenvironment and the current landscape to engage these cells includes check point inhibitors, immune cell engagers, and CAR cells
- ABBV-303 is a tumor targeting T and NK cell immune engager with potent cytotoxicity and immune cell modulation properties
- Immune cell activation, pro-inflammatory cytokine release, and cytotoxicity have been demonstrated with ABBV-303 using in-vivo and ex-vivo platforms